ICD-10: C81.76

ICD-10 code C81.76 refers specifically to "Other Hodgkin lymphoma, intrapelvic lymph nodes." This classification falls under the broader category of Hodgkin lymphoma, which is a type of lymphatic cancer characterized by the presence of Reed-Sternberg cells. Below is a detailed clinical description and relevant information regarding this diagnosis code.

Clinical Description of Hodgkin Lymphoma

Overview

Hodgkin lymphoma (HL) is a malignancy of the lymphatic system, which is part of the immune system. It is distinguished from non-Hodgkin lymphoma by the presence of Reed-Sternberg cells, which are large, abnormal lymphocytes. The disease can affect lymph nodes in various regions of the body, including the neck, armpits, abdomen, and pelvis.

Types of Hodgkin Lymphoma

Hodgkin lymphoma is classified into several subtypes, with the most common being:
- Classical Hodgkin Lymphoma (cHL): This includes nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted subtypes.
- Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A rarer form characterized by a different type of Reed-Sternberg cell.

C81.76 Specifics

The code C81.76 specifically denotes cases where Hodgkin lymphoma is present in the intrapelvic lymph nodes. This indicates that the lymphoma has localized to lymph nodes situated within the pelvic cavity, which can include nodes associated with the iliac vessels and other pelvic structures.

Clinical Presentation

Patients with Hodgkin lymphoma may present with a variety of symptoms, including:
- Lymphadenopathy: Swelling of lymph nodes, which may be painless.
- B Symptoms: These include fever, night sweats, and unexplained weight loss.
- Abdominal Symptoms: If the intrapelvic lymph nodes are involved, patients may experience abdominal pain or discomfort, changes in bowel habits, or urinary symptoms due to pressure on surrounding organs.

Diagnosis

Diagnosis of Hodgkin lymphoma typically involves:
- Physical Examination: Assessment of lymph nodes and other symptoms.
- Imaging Studies: CT scans or PET scans to evaluate the extent of the disease and locate affected lymph nodes.
- Biopsy: A definitive diagnosis is made through a biopsy of the affected lymph node, where the presence of Reed-Sternberg cells can be confirmed.

Treatment

Treatment for Hodgkin lymphoma, including cases coded as C81.76, may involve:
- Chemotherapy: Often the first line of treatment, using a combination of drugs to target cancer cells.
- Radiation Therapy: May be used in conjunction with chemotherapy, especially if the disease is localized.
- Stem Cell Transplant: Considered in cases of relapse or refractory disease.

Prognosis

The prognosis for Hodgkin lymphoma is generally favorable, particularly when diagnosed early. The five-year survival rate can be as high as 85% or more, depending on various factors such as the stage of the disease, the patient's age, and overall health.

Conclusion

ICD-10 code C81.76 is crucial for accurately documenting cases of Hodgkin lymphoma that specifically involve the intrapelvic lymph nodes. Understanding the clinical implications, diagnostic processes, and treatment options associated with this code is essential for healthcare providers managing patients with this condition. Proper coding not only aids in treatment planning but also ensures appropriate billing and resource allocation in healthcare settings.

Hodgkin lymphoma, particularly the variant classified under ICD-10 code C81.76, refers to "Other Hodgkin lymphoma, intrapelvic lymph nodes." This specific classification encompasses a range of clinical presentations, signs, symptoms, and patient characteristics that are essential for diagnosis and management. Below is a detailed overview of these aspects.

Clinical Presentation

General Overview

Hodgkin lymphoma is a type of lymphatic system cancer characterized by the presence of Reed-Sternberg cells. The intrapelvic variant indicates that the lymphoma is localized to the lymph nodes within the pelvic region, which can lead to specific clinical manifestations.

Signs and Symptoms

Patients with C81.76 may present with a variety of signs and symptoms, which can include:

• Lymphadenopathy: Swelling of lymph nodes, particularly in the pelvic area, which may be palpable during a physical examination.
• Abdominal Pain or Discomfort: Due to the enlargement of lymph nodes in the pelvis, patients may experience pain or a feeling of fullness in the lower abdomen.
• B Symptoms: These are systemic symptoms commonly associated with Hodgkin lymphoma, including:
• Fever: Unexplained fevers that may be intermittent.
• Night Sweats: Profuse sweating during the night that can soak clothing and bedding.
• Weight Loss: Unintentional weight loss over a short period, often exceeding 10% of body weight.
• Fatigue: A general feeling of tiredness or lack of energy that is not relieved by rest.
• Itching: Some patients report generalized itching, which can be distressing.

Patient Characteristics

Certain demographic and clinical characteristics are often observed in patients diagnosed with Hodgkin lymphoma, including:

• Age: Hodgkin lymphoma has a bimodal age distribution, commonly affecting young adults (ages 15-35) and older adults (over 55).
• Gender: Males are generally at a higher risk compared to females, with a male-to-female ratio of approximately 1.5:1.
• History of Infections: Some studies suggest a link between Hodgkin lymphoma and previous infections, such as Epstein-Barr virus (EBV).
• Family History: A family history of lymphoma or other hematological malignancies may increase risk.
• Immunocompromised Status: Patients with weakened immune systems, such as those with HIV/AIDS or those on immunosuppressive therapy, may have a higher incidence of Hodgkin lymphoma.

Diagnostic Considerations

Diagnosis of C81.76 typically involves a combination of clinical evaluation, imaging studies (such as CT scans), and histopathological examination of lymph node biopsies. The presence of Reed-Sternberg cells in the biopsy is a definitive indicator of Hodgkin lymphoma.

Imaging Studies

• CT Scans: Often used to assess the extent of lymphadenopathy and to evaluate the involvement of intrapelvic lymph nodes.
• PET Scans: May be utilized to determine metabolic activity of the lymph nodes and to assess for potential metastasis.

Conclusion

Understanding the clinical presentation, signs, symptoms, and patient characteristics associated with ICD-10 code C81.76 is crucial for timely diagnosis and effective management of Hodgkin lymphoma affecting intrapelvic lymph nodes. Early recognition of symptoms and appropriate diagnostic imaging can significantly impact treatment outcomes and patient prognosis. If you suspect Hodgkin lymphoma in a patient, a thorough clinical evaluation and prompt referral for further investigation are essential steps in the management process.

ICD-10 code C81.76 refers specifically to "Other Hodgkin lymphoma, intrapelvic lymph nodes." This classification falls under the broader category of Hodgkin lymphoma, which is a type of lymphatic cancer. Below are alternative names and related terms associated with this specific code:

Alternative Names for C81.76

1. Hodgkin Lymphoma, Other Type: This term encompasses various forms of Hodgkin lymphoma that do not fit into the more commonly recognized subtypes, such as nodular sclerosis or mixed cellularity.

2. Hodgkin Disease: This is an older term that is still used interchangeably with Hodgkin lymphoma, referring to the same condition.

3. Lymphoma, Hodgkin Type: This phrase emphasizes the lymphatic origin of the disease while specifying that it is a Hodgkin type.

Related Terms

1. Intraperitoneal Lymph Nodes: While not a direct synonym, this term relates to the anatomical location of the lymph nodes affected in C81.76, as intrapelvic lymph nodes are part of the broader intraperitoneal lymphatic system.

2. Lymphadenopathy: This term describes the condition of swollen lymph nodes, which is a common symptom of Hodgkin lymphoma.

3. Lymphoma: A general term for cancers that originate in the lymphatic system, which includes both Hodgkin and non-Hodgkin lymphomas.

4. Stage IV Hodgkin Lymphoma: In some contexts, C81.76 may be associated with advanced stages of Hodgkin lymphoma, particularly when it involves lymph nodes in the pelvis.

5. Hodgkin Lymphoma with Pelvic Involvement: This phrase can be used to describe cases where the disease specifically affects the lymph nodes located in the pelvic region.

Conclusion

Understanding the alternative names and related terms for ICD-10 code C81.76 is essential for accurate diagnosis, treatment planning, and coding in medical records. These terms help healthcare professionals communicate effectively about the condition and ensure that patients receive appropriate care based on the specific characteristics of their lymphoma.

The diagnosis of Other Hodgkin lymphoma, specifically coded as ICD-10 code C81.76, which refers to cases involving intrapelvic lymph nodes, follows a set of established clinical criteria and diagnostic procedures. Understanding these criteria is essential for accurate coding and treatment planning.

Diagnostic Criteria for Other Hodgkin Lymphoma (C81.76)

1. Clinical Presentation

Patients with Hodgkin lymphoma may present with a variety of symptoms, which can include:
- Lymphadenopathy: Swelling of lymph nodes, particularly in the cervical, axillary, or inguinal regions.
- B Symptoms: These include fever, night sweats, and unexplained weight loss, which are significant indicators of lymphoma.
- Abdominal Symptoms: In cases where intrapelvic lymph nodes are involved, patients may experience abdominal pain or discomfort, changes in bowel habits, or urinary symptoms due to pressure effects.

2. Imaging Studies

Imaging plays a crucial role in diagnosing Hodgkin lymphoma and assessing the extent of the disease:
- CT Scans: A computed tomography (CT) scan of the chest, abdomen, and pelvis is typically performed to identify enlarged lymph nodes and assess their location, including intrapelvic involvement.
- PET Scans: Positron emission tomography (PET) scans may be utilized to evaluate metabolic activity in lymph nodes, helping to distinguish between benign and malignant processes.

3. Histopathological Examination

A definitive diagnosis of Hodgkin lymphoma requires histological confirmation:
- Biopsy: A lymph node biopsy (excisional or incisional) is performed to obtain tissue samples. The presence of Reed-Sternberg cells, which are characteristic of Hodgkin lymphoma, is essential for diagnosis.
- Immunohistochemistry: This technique is used to identify specific markers on the Reed-Sternberg cells, aiding in the classification of the lymphoma subtype.

4. Staging

The Ann Arbor staging system is commonly used to determine the extent of Hodgkin lymphoma:
- Stage I: Involvement of a single lymph node region.
- Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm.
- Stage III: Involvement of lymph node regions on both sides of the diaphragm.
- Stage IV: Disseminated involvement of one or more extralymphatic organs.

For C81.76, the focus is on the involvement of intrapelvic lymph nodes, which may indicate a more advanced stage of the disease.

5. Laboratory Tests

Additional laboratory tests may support the diagnosis:
- Complete Blood Count (CBC): To assess for anemia or leukopenia, which can occur in lymphoma.
- Liver and Kidney Function Tests: To evaluate organ function, especially if systemic symptoms are present.

Conclusion

The diagnosis of Other Hodgkin lymphoma involving intrapelvic lymph nodes (ICD-10 code C81.76) is a multifaceted process that includes clinical evaluation, imaging studies, histopathological confirmation, and staging. Accurate diagnosis is crucial for determining the appropriate treatment plan and improving patient outcomes. If you have further questions or need more specific information regarding treatment protocols or coding guidelines, feel free to ask!

Hodgkin lymphoma, classified under ICD-10 code C81.76, refers to a specific type of Hodgkin lymphoma that affects the intrapelvic lymph nodes. The treatment approaches for this condition typically involve a combination of chemotherapy, radiation therapy, and, in some cases, stem cell transplantation. Below is a detailed overview of the standard treatment modalities for this type of lymphoma.

Overview of Hodgkin Lymphoma

Hodgkin lymphoma is a malignancy of the lymphatic system characterized by the presence of Reed-Sternberg cells. It is generally classified into two main types: classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. The treatment for Hodgkin lymphoma is often determined by the stage of the disease, the patient's overall health, and specific characteristics of the lymphoma.

Standard Treatment Approaches

1. Chemotherapy

Chemotherapy is the cornerstone of treatment for Hodgkin lymphoma, including cases involving intrapelvic lymph nodes. The most commonly used chemotherapy regimen is ABVD, which consists of:

• Adriamycin (doxorubicin)
• Bleomycin
• Vinblastine
• Dacarbazine

This regimen is typically administered in cycles over several months, with the total number of cycles depending on the stage of the disease and the patient's response to treatment. For advanced stages, additional cycles or alternative regimens may be considered.

2. Radiation Therapy

Radiation therapy is often used in conjunction with chemotherapy, especially for localized disease. In cases where intrapelvic lymph nodes are involved, targeted radiation can help eliminate residual disease after chemotherapy. The use of radiation therapy is particularly effective in early-stage Hodgkin lymphoma and can be tailored to minimize exposure to surrounding healthy tissues.

3. Stem Cell Transplantation

For patients with relapsed or refractory Hodgkin lymphoma, high-dose chemotherapy followed by autologous stem cell transplantation may be recommended. This approach allows for the administration of higher doses of chemotherapy, which can be more effective in eradicating the disease. The patient's own stem cells are collected prior to high-dose treatment and reinfused afterward to restore bone marrow function.

4. Targeted Therapy and Immunotherapy

Recent advancements in treatment have introduced targeted therapies and immunotherapies for Hodgkin lymphoma. For example, brentuximab vedotin (Adcetris®) is an antibody-drug conjugate that targets CD30, a protein expressed on Reed-Sternberg cells. This treatment can be particularly beneficial for patients who have not responded to standard therapies or have relapsed after initial treatment.

5. Clinical Trials

Patients with Hodgkin lymphoma may also consider participation in clinical trials, which can provide access to new and innovative therapies that are not yet widely available. These trials often explore novel combinations of existing treatments or entirely new agents.

Conclusion

The treatment of Hodgkin lymphoma affecting intrapelvic lymph nodes (ICD-10 code C81.76) typically involves a multidisciplinary approach, combining chemotherapy, radiation therapy, and potentially stem cell transplantation or targeted therapies. The choice of treatment is highly individualized, taking into account the specific characteristics of the lymphoma and the patient's overall health. Ongoing research and clinical trials continue to enhance the understanding and management of this disease, offering hope for improved outcomes for patients.